Video Quality Speed 00:00 03:41 Brewers draftee Marco Dinges survives near-fatal bout with rare disease to live out his ...

The FDA has approved Gamifant as the first-ever treatment for macrophage activation syndrome in Still’s disease for adults ...

The approval was supported by pooled data from 2 open-label, single arm trials: the phase 2 NI-0501-06 study and the phase 3 EMERALD trial.

Gamifant marks the first-ever FDA-approved treatment for both adult and pediatric patients with hemophagocytic ...

The US Food and Drug Administration (FDA) has approved Sobi's Gamifant (emapalumab) to treat adults and children with ...

HLH, a cytokine-mediated hyperinflammation syndrome, causes fever, pancytopenia, and hemophagocytosis and is often fatal. Antiinflammatory agents, etoposide, and interferon-γ antibody are the ...

Eight-year-old Jackson Broome, a brave young boy from Carteret County, is capturing hearts across the nation as he battles hemophagocytic lymphohistiocytosis (HLH), a rare and life-threatening immune ...

“HLH/MAS in Still disease is a serious and potentially fatal complication where patients can experience intense hyperinflammation and even multiple organ failure,” said Lydia Abad-Franch, ...

Haemophagocytic lymphohistiocytosis (HLH) syndrome induced by dengue is a complication, which is rare and life threatening. Doctors say that it is caused by an abnormal response of the body's ...

They included 15 patients with rheumatologic disease–associated HLH (median age at diagnosis, 5 years; 73.3% women) who received at least one dose of emapalumab between November 20, ...

Stockholm, Sweden Monday, June 30, 2025, 10:00 Hrs [IST] ...

Emapalumab is approved for both adults and pediatric (newborn and older) patients with MAS in Still disease with an inadequate response or intolerance to glucocorticoids, or with recurrent MAS.